)
)
Passage Bio Investor Relations Material
Latest events
Study Result
Passage Bio
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Passage Bio Inc
Access all reports
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The Company's lead products in clinical development are TB-403, a novel oligonucleotide modulator of thromboxane receptors (TXRs) and P7C3, a small molecule oral GPCR modulator that targets the vasoactive intestinal peptide (VIP). The company has a bold vision to fulfill the promise of gene therapy by delivering medicines that provide a cure for previously incurable diseases
Key slides for Passage Bio Inc
Corporate Presentation
Passage Bio Inc
Corporate Presentation
Passage Bio Inc
Latest articles
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Ticker symbol
PASG
Country
🇺🇸 United States